In the News
Flex your outsourcing model to maximize drug development
Timothy King discusses the rationale, advantages and disadvantages behind strategically selecting the right outsourcing model.
PPD picks up Bioclinica’s global site business
AES has acquired the clinical research site business of Bioclinica, expanding AES’ global footprint and solidifying its leadership position in patient access and site conduct.
PPD signed on as preferred provider for Harbour BioMed
Harbour BioMed (HBM) and PPD have announced a strategic collaboration to develop HBM’s innovative therapeutics in the fields of oncology and immunology.
PPD extends Japanese footprint with exclusive collaboration
Evidera has entered into an exclusive collaboration agreement with Clinical Study Support, Inc., extending both organizations’ capabilities to deliver more robust consulting and analytical capabilities.
PPD Collaborates With Biopharma Company On Oncology, Immunology Therapies
Harbour BioMed (HBM) has selected PPD as its preferred global contract research partner to conduct clinical studies on its internal research pipelines.
Harbour BioMed, PPD pen cancer and immunology drug development collab
Biotech Harbour BioMed has teamed up with CRO PPD to work on creating new oncology and immunology meds.
Wilmington pharma nabs contract with global oncology outfit
North Carolina CRO has landed a contract with a global biopharmaceutical company with a quickly expanding research portfolio – adding to the firm's prestige in oncology and immunology development.
ADC characterization
Christopher Bianchetti, Henry Parker, Kit Hanson and Stephen Gacheru discuss the potential of antibody-drug conjugates for the biopharmaceutical industry.
Five-year study to examine how healthy brains age: ‘Research is urgently needed,’ says AES
PPD business unit Accelerated Enrollment Solutions initiates the Synexus HealthyMinds Registry, which aims to register 30,000 adults for the study.